WO2009078366A1 - α-リポ酸ナノ粒子およびその調製方法 - Google Patents

α-リポ酸ナノ粒子およびその調製方法 Download PDF

Info

Publication number
WO2009078366A1
WO2009078366A1 PCT/JP2008/072699 JP2008072699W WO2009078366A1 WO 2009078366 A1 WO2009078366 A1 WO 2009078366A1 JP 2008072699 W JP2008072699 W JP 2008072699W WO 2009078366 A1 WO2009078366 A1 WO 2009078366A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipoic acid
divalent metal
producing
same
aqueous dispersion
Prior art date
Application number
PCT/JP2008/072699
Other languages
English (en)
French (fr)
Inventor
Kazuhisa Sugimoto
Hiromi Nishiura
Yoko Yamaguchi
Keiichi Hirata
Yoshiki Kubota
Original Assignee
Ezaki Glico Co., Ltd.
Nanoegg Research Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ezaki Glico Co., Ltd., Nanoegg Research Laboratories, Inc. filed Critical Ezaki Glico Co., Ltd.
Priority to KR1020107015636A priority Critical patent/KR101441523B1/ko
Priority to JP2009546249A priority patent/JP4647706B2/ja
Priority to CN200880126792XA priority patent/CN101945654B/zh
Priority to EP20080863352 priority patent/EP2241314B1/en
Priority to CA 2707010 priority patent/CA2707010A1/en
Priority to US12/746,795 priority patent/US9079874B2/en
Publication of WO2009078366A1 publication Critical patent/WO2009078366A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

安定なα-リポ酸を提供すること。α-リポ酸ナノ粒子の製造方法であって、α-リポ酸と非イオン性界面活性剤とを含む水性分散液を調製する工程;該水性分散液に、２価金属塩を添加する工程であって、該２価金属塩が、２価金属ハロゲン化物、２価金属酢酸化物または２価金属グルコン酸化物である、工程;および該２価金属塩を添加した水性分散液に、アルカリ金属炭酸化物またはアルカリ金属リン酸化物を添加して、α-リポ酸ナノ粒子を形成させる工程を包含する、方法。
PCT/JP2008/072699 2007-12-14 2008-12-12 α-リポ酸ナノ粒子およびその調製方法 WO2009078366A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020107015636A KR101441523B1 (ko) 2007-12-14 2008-12-12 α-리포산 나노입자들 및 이의 제조 방법
JP2009546249A JP4647706B2 (ja) 2007-12-14 2008-12-12 α−リポ酸ナノ粒子およびその調製方法
CN200880126792XA CN101945654B (zh) 2007-12-14 2008-12-12 α-硫辛酸纳米颗粒及其制备方法
EP20080863352 EP2241314B1 (en) 2007-12-14 2008-12-12 Alpha-lipoic acid nanoparticle and method for producing the same
CA 2707010 CA2707010A1 (en) 2007-12-14 2008-12-12 .alpha.-lipoic acid nanoparticles and methods for preparing thereof
US12/746,795 US9079874B2 (en) 2007-12-14 2008-12-12 α-Lipoic acid nanoparticles and methods for preparing thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007324041 2007-12-14
JP2007-324041 2007-12-14

Publications (1)

Publication Number Publication Date
WO2009078366A1 true WO2009078366A1 (ja) 2009-06-25

Family

ID=40795482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072699 WO2009078366A1 (ja) 2007-12-14 2008-12-12 α-リポ酸ナノ粒子およびその調製方法

Country Status (7)

Country Link
US (1) US9079874B2 (ja)
EP (1) EP2241314B1 (ja)
JP (2) JP4647706B2 (ja)
KR (1) KR101441523B1 (ja)
CN (1) CN101945654B (ja)
CA (1) CA2707010A1 (ja)
WO (1) WO2009078366A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137335A1 (ja) * 2009-05-29 2010-12-02 江崎グリコ株式会社 α－リポ酸ナノ粒子を含有する、ターンオーバー促進用組成物
JP2014520541A (ja) * 2011-07-15 2014-08-25 プレイオン 透明な栄養マイクロエマルジョンの配合物
JPWO2012165468A1 (ja) * 2011-05-31 2015-02-23 株式会社ナノエッグ 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20111452A1 (it) * 2011-07-29 2013-01-30 Istituto Biochimico Naz Sav Io Srl Soluzione basica di acido alfa-lipoico e suoi usi
KR101504907B1 (ko) * 2013-01-29 2015-03-25 코스맥스 주식회사 알파리포산을 함유하는 비수계 화장료 조성물
AU2014215421A1 (en) 2013-02-05 2015-08-13 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
CN103226103B (zh) * 2013-04-04 2015-02-04 哈尔滨师范大学 一种汞离子比色检测探针及其应用方法
JP2015105249A (ja) * 2013-11-29 2015-06-08 富士フイルム株式会社 化粧料
CN103690492A (zh) * 2013-12-16 2014-04-02 常熟富士莱医药化工有限公司 一种硫辛酸颗粒的制备方法
JP2016088902A (ja) * 2014-11-07 2016-05-23 ポーラ化成工業株式会社 徐放担体
EP3235493A4 (en) * 2014-12-19 2018-05-30 Sekisui Chemical Co., Ltd. Preparation
WO2016160436A1 (en) * 2015-03-27 2016-10-06 Andrew Teng Tiny particles for control-release and method of manufacturing the same
EP3421131A1 (en) 2017-06-30 2019-01-02 Blink AG A sample cartridge for incubating and/or analyzing a dispersion of particles, cells or droplets
JP2019069912A (ja) * 2017-10-06 2019-05-09 株式会社シャネル化粧品技術開発研究所 非水系皮膚外用組成物およびその製造方法
CN108553458B (zh) * 2018-04-25 2020-06-30 四川大学 一种抗肿瘤纳米药物
EP3860581A4 (en) * 2018-10-06 2022-07-20 Btv Holding, Llc CYSTEAMINE ZINC COMPLEX AND METHODS OF USE OF A CYSTEAMINE ZINC COMPLEX
US10799455B1 (en) 2019-11-11 2020-10-13 King Abdulaziz University Micellles containing alpha lipoic acid as a transdermal drug delivery system
JP7333751B2 (ja) * 2019-12-20 2023-08-25 ライオン株式会社 ヒト抗菌ペプチド産生促進剤
CN114010522B (zh) * 2021-12-22 2023-10-13 郑州大学 一种硫辛酸混合胶束及其制备方法和应用
CN116637203A (zh) * 2022-02-15 2023-08-25 四川大学 硫辛酸纳米粒子在制备氧化应激相关疾病治疗药物中的应用
CN115844892B (zh) * 2022-09-21 2024-04-19 中国药科大学 二硫键修饰的纳米聚集体及其制备方法和应用
CN115957345B (zh) * 2023-01-10 2024-10-11 北京百替生物技术有限公司 一种用于变应性鼻炎治疗的pH响应性靶向纳米递送系统及其制备方法和应用

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085328A2 (de) * 2001-02-11 2002-10-31 Aquanova German Solubilisate Technologies (Agt) Gmbh Verfahren zur herstellung eines wirkstoffkonzentrats sowie wirkstoffkonzentrat
JP2004161739A (ja) 2002-09-25 2004-06-10 Ltt Bio-Pharma Co Ltd レチノイン酸ナノカプセル
JP2005002096A (ja) 2003-05-21 2005-01-06 Oga Research:Kk α−リポ酸含有水性製剤
JP2005037267A (ja) 2003-07-16 2005-02-10 Ishikawajima Harima Heavy Ind Co Ltd パルスレーザ装置の出力モニタ方法及び装置
JP2005037268A (ja) 2003-07-16 2005-02-10 Cosmo Instruments Co Ltd 流量検査装置
JP2005070413A (ja) 2003-08-25 2005-03-17 Alps Electric Co Ltd ホルダ付光学素子及びその製造方法
WO2005037268A1 (ja) * 2003-10-15 2005-04-28 Ltt Bio-Pharma Co., Ltd. 多価金属無機塩被覆レチノイン酸ナノ粒子含有組成物
WO2005089412A2 (en) * 2004-03-17 2005-09-29 Takemoto Arnold C Tissue detoxification and health supplements and methods of making and using them
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
JP2006129841A (ja) 2004-11-09 2006-05-25 Nof Corp α−リポ酸含有水性組成物
JP2006219467A (ja) * 2005-02-10 2006-08-24 Oriza Yuka Kk 脂肪蓄積阻害剤
JP2006257010A (ja) 2005-03-16 2006-09-28 Yokohama Yushi Kogyo Kk α−リポ酸水溶性組成物、それを含む飲食品、化粧料及びその製造方法
JP2007016000A (ja) 2005-07-11 2007-01-25 Taiyo Kagaku Co Ltd チオクト酸含有組成物
JP2007513994A (ja) * 2004-08-18 2007-05-31 アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポ酸濃縮物
JP2007302570A (ja) * 2006-05-08 2007-11-22 Fancl Corp チオクト酸を含有する徐放性製剤
JP2008206517A (ja) * 2007-01-31 2008-09-11 Fancl Corp 超臨界流体を用いた油脂コーティング複合化粒子の製法及び複合化粒子

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042833A1 (de) 2000-08-30 2002-03-14 Basf Ag Feste Zubereitungen mit einer Multi-Kern Struktur
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1551457A1 (en) 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
JP2006199589A (ja) 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
EP1674093A4 (en) 2003-10-15 2009-12-09 Nanoegg Res Lab Inc METHOD OF CHECKING THE PARTICLE SIZE OF RETINOLIC ACID NANOTEILS WITH A COATING OF POLYVALENT INORGANIC METAL SALT AND NANOTEHTES OBTAINED BY THE CONTROL PROCEDURE
WO2005060935A1 (ja) * 2003-12-24 2005-07-07 Ltt Bio-Pharma Co., Ltd. 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
WO2005070413A1 (ja) * 2004-01-23 2005-08-04 Japan Science And Technology Agency レチノイン酸を含有する糖尿病治療薬
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
JP4849792B2 (ja) 2004-09-14 2012-01-11 オリザ油化株式会社 美容用組成物
US20090226408A1 (en) * 2005-06-24 2009-09-10 Kaneka Corporation Anti-fatigue composition
JP2007091686A (ja) 2005-09-30 2007-04-12 Ltt Bio-Pharma Co Ltd ヒノキチオールを含有するナノ粒子
US20090131537A1 (en) * 2007-11-14 2009-05-21 Wille Jr John Jacob Wound healing compositions

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085328A2 (de) * 2001-02-11 2002-10-31 Aquanova German Solubilisate Technologies (Agt) Gmbh Verfahren zur herstellung eines wirkstoffkonzentrats sowie wirkstoffkonzentrat
JP2004161739A (ja) 2002-09-25 2004-06-10 Ltt Bio-Pharma Co Ltd レチノイン酸ナノカプセル
JP2005002096A (ja) 2003-05-21 2005-01-06 Oga Research:Kk α−リポ酸含有水性製剤
JP2005037267A (ja) 2003-07-16 2005-02-10 Ishikawajima Harima Heavy Ind Co Ltd パルスレーザ装置の出力モニタ方法及び装置
JP2005037268A (ja) 2003-07-16 2005-02-10 Cosmo Instruments Co Ltd 流量検査装置
JP2005070413A (ja) 2003-08-25 2005-03-17 Alps Electric Co Ltd ホルダ付光学素子及びその製造方法
WO2005037268A1 (ja) * 2003-10-15 2005-04-28 Ltt Bio-Pharma Co., Ltd. 多価金属無機塩被覆レチノイン酸ナノ粒子含有組成物
WO2005089412A2 (en) * 2004-03-17 2005-09-29 Takemoto Arnold C Tissue detoxification and health supplements and methods of making and using them
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
JP2007513994A (ja) * 2004-08-18 2007-05-31 アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポ酸濃縮物
JP2006129841A (ja) 2004-11-09 2006-05-25 Nof Corp α−リポ酸含有水性組成物
JP2006219467A (ja) * 2005-02-10 2006-08-24 Oriza Yuka Kk 脂肪蓄積阻害剤
JP2006257010A (ja) 2005-03-16 2006-09-28 Yokohama Yushi Kogyo Kk α−リポ酸水溶性組成物、それを含む飲食品、化粧料及びその製造方法
JP2007016000A (ja) 2005-07-11 2007-01-25 Taiyo Kagaku Co Ltd チオクト酸含有組成物
JP2007302570A (ja) * 2006-05-08 2007-11-22 Fancl Corp チオクト酸を含有する徐放性製剤
JP2008206517A (ja) * 2007-01-31 2008-09-11 Fancl Corp 超臨界流体を用いた油脂コーティング複合化粒子の製法及び複合化粒子

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNICA JACOBSON ET AL., INT. J. CANCER, vol. 102, 2002, pages 212 - 219
LESTER J. REED ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 75, 1953, pages 1267
ROBBERT CRETON ET AL., INT. J. DEV. BIOL., vol. 39, 1995, pages 409 - 414
See also references of EP2241314A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137335A1 (ja) * 2009-05-29 2010-12-02 江崎グリコ株式会社 α－リポ酸ナノ粒子を含有する、ターンオーバー促進用組成物
JPWO2012165468A1 (ja) * 2011-05-31 2015-02-23 株式会社ナノエッグ 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物
JP2014520541A (ja) * 2011-07-15 2014-08-25 プレイオン 透明な栄養マイクロエマルジョンの配合物

Also Published As

Publication number Publication date
CN101945654A (zh) 2011-01-12
EP2241314A4 (en) 2012-08-08
CA2707010A1 (en) 2009-06-25
EP2241314A1 (en) 2010-10-20
JP5547612B2 (ja) 2014-07-16
US20110065781A1 (en) 2011-03-17
KR101441523B1 (ko) 2014-09-17
JP4647706B2 (ja) 2011-03-09
KR20100101660A (ko) 2010-09-17
CN101945654B (zh) 2012-06-27
JPWO2009078366A1 (ja) 2011-04-28
EP2241314B1 (en) 2013-04-17
US9079874B2 (en) 2015-07-14
JP2011063606A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
WO2009078366A1 (ja) α-リポ酸ナノ粒子およびその調製方法
WO2008108409A1 (ja) 第四級アンモニウム塩をゲスト化合物とする包接水和物
IL186680A0 (en) Method for producing methylglycine-n,n-diethanoic acid trialkalimetal salts with a low by-product content
EP2554050A4 (en) COMBINED CHLORINMS AND MANUFACTURING AND USE METHOD THEREFOR
WO2012011774A3 (ko) 은 나노와이어의 제조방법
WO2005070888A3 (en) Process for the manufacture of 2,3-dichloropyridine
WO2009086193A3 (en) Hybrid vehicle systems
WO2008126374A1 (ja) 植物の耐アルカリ性向上剤及び耐アルカリ性向上方法
WO2007120352A3 (en) Method of preparing an overbased or neutral detergent
TWI455777B (zh) 銅粉之製造方法及銅粉
DE602006019626D1 (de) Eisenoxid enthaltend gefälltes kristallines titandioxid und zugehöriges herstellungsverfahren
WO2006132643A3 (en) Methods of making metal nanoprisms having a predetermined thickness
AU2010333959A8 (en) Organically chelated mineral compositions and methods thereof
WO2008111383A1 (ja) アルミ改質コロイダルシリカ及びその製造方法
CA2796471A1 (en) Composition comprising aluminum silicates and silver nanoparticles as bactericides
WO2011062420A3 (en) Nanoparticles for tumor-targeting and processes for the preparation thereof
EP2030960A3 (en) Polymerised inorganic-organic precursor solutions and sintered membranes
WO2011003805A3 (en) Leach-proof microcapsules, the method for preparation and use of leach-proof microcapsules
WO2009134822A3 (en) Fluorescent organic nanoparticles
WO2006094945A3 (de) Verfahren zur herstellung optisch aktiver alkohole durch enzymatische reduktion
WO2011080656A3 (en) Methods for producing aluminum trifluoride
WO2011029716A3 (en) Concentrated solutions comprising group vi metal, group viii metal, and phosphorus
WO2011027163A3 (en) Fire resistant glazings
WO2008132943A1 (ja) メソポーラスシリカ膜
WO2009057435A1 (ja) 表面調整アルミニウム鋳造物の製造方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126792.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863352

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009546249

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2707010

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 3469/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107015636

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008863352

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12746795

Country of ref document: US